OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
What is the plausibility that all drugs will be designed by computers by the end of the decade?	159
Advances in ion channel high throughput screening: where are we in 2023?	124
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	78
Lessons learned from phenotypic drug discovery efforts	76
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	73
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	69
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer	68
γ-Secretase: once and future drug target for Alzheimer’s disease	66
Advances in the discovery of drugs that treat pulmonary arterial hypertension	57
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	54
Strategies for targeting RNA with small molecule drugs	51
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	49
Methods in marine natural product drug discovery: what’s new?	46
Tools and techniques for the discovery of therapeutic aptamers: recent advances	45
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	43
An update on knowledge graphs and their current and potential applications in drug discovery	42
The machine learning life cycle and the cloud: implications for drug discovery	37
Guided structure-based ligand identification and design via artificial intelligence modeling	37
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	36
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	36
The rules often neglected in current medicinal chemistry	34
A cautionary tale of paradox and false positives in cannabidiol research	34
Molecular hybridization: a powerful tool for multitarget drug discovery	32
Virtual screening: hope, hype, and the fine line in between	32
Water in drug design: pitfalls and good practices	31

Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	29
The discovery and development of RNA-based therapies for treatment of HIV-1 infection	28
Drug design strategies for the treatment azole-resistant candidiasis	27
Novel hydrogels: are they poised to transform 3D cell-based assay systems in early drug discovery?	27
An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma	27
Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery	27